SUPRIYA Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹277Cr
- +50.5% YoY
- +34.5% QoQ
- Net profit
- ₹74Cr
- +48% YoY
- +48% QoQ
- Margin
- 35%
- −2 pp YoY
- 0 pp QoQ
Guidance rank: #32 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
What the Q4 FY26 call signalled
3 of 4 strong
The short version
- Supriya Lifescience targets approximately 20% annual revenue growth, aiming to achieve INR 1,000 crores by FY27. - Growth driven by sustained demand in core therapeutic segments: anesthetics, antibiotics, anti-anxiety, vitamins, and ADHD. - Plan to launch 3 to 4 new products annually, including 2 new launches each in anesthetics and ADHD segments in FY27. - Cardiovascular advanced intermediate product scaling up, expected to contribute increasingly over 2-3 years. - New capacities from debottlenecking and new blocks (F block and expansions) will add 150-200 KL over 2 years to support growth. - Backward integration completed to support scalability and cost efficiency. - Ambernath and upcoming Patalganga facilities expected to accelerate growth beyond FY27. - Growth in U.S. - Supriya Lifescience targets approximately 20% annual revenue growth, aiming to reach INR1,000 crores by FY27.
From Supriya Lifescience Ltd's Q4 FY26 earnings-call transcript · updated 22 Jun 2026.
Revenue & Sales Performance
- Supriya Lifescience targets approximately 20% annual revenue growth, aiming to achieve INR 1,000 crores by FY27.
- Growth driven by sustained demand in core therapeutic segments: anesthetics, antibiotics, anti-anxiety, vitamins, and ADHD.
- Plan to launch 3 to 4 new products annually, including 2 new launches each in anesthetics and ADHD segments in FY27.
- Cardiovascular advanced intermediate product scaling up, expected to contribute increasingly over 2-3 years.
- New capacities from debottlenecking and new blocks (F block and expansions) will add 150-200 KL over 2 years to support growth.
- Backward integration completed to support scalability and cost efficiency.
- Ambernath and upcoming Patalganga facilities expected to accelerate growth beyond FY27.
2 more points from Supriya Lifescience Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Supriya Lifescience Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Continued capacity expansion with the addition of the F block at Lote Parshuram plant, adding 150-200 KL capacity over the next 2 years with INR40-50 crores capex.
- Development of the Patalganga facility with all clearances received; Phase 1 includes two API/advanced intermediate blocks and two formulation blocks, planned capex around INR200 crores over the next 2 years.
- Focus on capacity building to support growth, especially for CMO/CDMO opportunities and to handle scaling product volumes.
- Total capex for FY26 was INR152 crores, mainly spent on Ambernath facility, maintenance, Ribo Block, and formulation plant needs.
2 more points from Supriya Lifescience Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Supriya Lifescience Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Cardiovascular intermediate: Advanced discussions for 300 metric tons capacity, expected to be nearly fully utilized in FY27, but full potential to scale over 2-3 years.
- Contracts locked with 3-4 large customers for the cardiovascular product.
- Liquid anesthetic (sevoflurane formulation): CMO discussions at advanced stage, but no firm term sheet signed yet.
- DSM contract stabilized with around 3 tons/month volume; contributing approx. INR30-35 crores in FY26 with peak expected at INR60 crores in FY27.
- No signed agreement yet for GLP-1 product development; discussions are at an advanced stage.
- New product launches and existing basket growing steadily.
2 more points from Supriya Lifescience Ltd's call on order book
Create a free account to keep reading this call
Supriya Lifescience Ltd — Quarterly revenue & net profit
Supriya Lifescience Ltd Q4 FY26 results — key figures
| ₹ Cr | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 277 | 184 | +50.5% | 206 | +34.5% |
| Operating profit (EBITDA) | 98 | 68 | +44.1% | 72 | +36.1% |
| Operating margin | 35% | 37% | -2 pp | 35% | 0 pp |
| Profit before tax | 92 | 64 | +43.8% | 67 | +37.3% |
| Net profit (PAT) | 74 | 50 | +48% | 50 | +48% |
| EPS (₹) | 9.22 | 6.26 | +47.3% | 6.17 | +49.4% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹206 Cr, net profit ₹29 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Supriya Lifescience's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharma (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pharmaceuticals (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Supriya Lifescience Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Supriya Lifescience Ltd Q1 FY27 results?
- Supriya Lifescience targets approximately 20% annual revenue growth, aiming to achieve INR 1,000 crores by FY27. - Growth driven by sustained demand in core therapeutic segments: anesthetics, antibiotics, anti-anxiety, vitamins, and ADHD. - Plan to launch 3 to 4 new products annually, including 2 new launches each in anesthetics and ADHD segments in FY27. - Cardiovascular advanced intermediate product scaling up, expected to contribute increasingly over 2-3 years. - New capacities from debottlenecking and new blocks (F block and expansions) will add 150-200 KL over 2 years to support growth. - Backward integration completed to support scalability and cost efficiency. - Ambernath and upcoming Patalganga facilities expected to accelerate growth beyond FY27. - Growth in U.S. - Supriya Lifescience targets approximately 20% annual revenue growth, aiming to reach INR1,000 crores by FY27.
What is Supriya Lifescience Ltd share price analysis?
Supriya Lifescience Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 29.9 with a market cap of ₹5,542. Investors should review the full earnings analysis for detailed insights.
Is Supriya Lifescience Ltd planning capital expenditure?
- Continued capacity expansion with the addition of the F block at Lote Parshuram plant, adding 150-200 KL capacity over the next 2 years with INR40-50 crores capex.
Keep Supriya Lifescience Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
